PepGen (PEPG)

PepGen’s core technology is its Enhanced Delivery Oligonucleotide, or EDO, platform. The platform links therapeutic oligonucleotides to proprietary cell-penetrating peptides designed to improve delivery into tissues that are difficult to reach. The company’s research emphasizes uptake in skeletal, cardiac, and smooth muscle, as well as potential delivery to the central nervous system. This delivery challenge is a major limitation for many genetic medicines, making PepGen’s platform the central differentiator of its strategy.

Its pipeline includes PGN-EDO51, a candidate designed for Duchenne muscular dystrophy patients whose mutations may be amenable to exon 51 skipping. Duchenne muscular dystrophy is a rare, progressive muscle-wasting disease that typically begins in childhood and has limited treatment options. PepGen is also developing PGN-EDODM1 for myotonic dystrophy type 1, a genetic disorder that can affect skeletal muscle, the heart, and other systems. Additional programs target other severe inherited conditions.

As a biotechnology company without a broad commercial product portfolio, PepGen’s value is closely tied to clinical trial progress, safety data, regulatory interactions, and the potential of its platform to support multiple medicines. Investors typically assess the company in the context of rare disease drug development, where scientific validation, patient selection, and manufacturing execution are critical.